Experienced finance exec becomes CFO at Diurnal

12 January 2017
diurnal-large

UK specialty pharma company Diurnal (AIM: DNL) has announced the appointment of Richard Bungay as chief financial officer (CFO).

Starting on Monday, Mr Bungay will take over from Ian Ardill, who is leaving to pursue other business opportunities, the company said in a statement.

"Richard’s experience will be invaluable as Diurnal strides towards realizing its ambition of becoming a world-leading endocrinology specialty pharma company"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical